Pay in 4 interest-free payments of $6.57 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Studies from Novo Nordisk show an almost 25% reduction in adverse kidney outcomes for diabetes patients with CKD, and the company is trying to get Wegovys indications expanded to include CKD before years end
Eli Lilly and Company Today LLY Eli Lilly and Company $1,197.88 +1.85 (+0.15%) As of 07/27/2026 03:59 PM Eastern 52-Week Range $623.78 $1,249.45 Dividend Yield 0.58% P/E Ratio 42.55 Price Target $1,283.64 This massive size plays to Eli Lilly's advantage as it seeks to expand its GLP-1 agonist program globally
Who qualifies for GLP-1 weight loss medication
Compounded GLP-I medications work by mimicking hormones that regulate appetite and digestion potentially leading to weight loss when combined with diet and exercise
US$ 25.88
US$ 28.29
US$ 28.60
US$ 29.23
